Uma nova perspectiva para o tratamento da depressão e transtornos de ansiedade?
Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?
We have reviewed the literature relating to the endocannabinoid system and its pharmacology; both original and review articles written in English were considered.
Cannabinoids are a group of compounds present in Cannabis Sativa (hemp), such as D9 -tetrahydrocannabinol, and their synthetic analogues. Research on their pharmacological profile led to the discovery of the endocannabinoid system in the mammalian brain. This system comprises at least two G-protein coupled receptors, CB1 and CB2 , their endogenous ligands (endocannabinoids; e.g. the fatty acid derivatives anandamide and 2-arachydonoyl glycerol), and the enzymes responsible for endocannabinoid synthesis and catabolism.
Endocannabinoids represent a class of neuromessengers, which are synthesized on demand and released from post-synaptic neurons to restrain the release of classical neurotransmitters from pre-synaptic terminals. This retrograde signalling modulates a variety of brain functions, including anxiety, fear and mood, whereby activation of CB1 receptors was shown to exert anxiolytic- and antidepressant-like effects in preclinical studies.
Animal experiments suggest that drugs promoting endocannabinoid action may represent a novel strategy for the treatment of depression and anxiety disorders.
For information click here.
This information is presented for educational purposes only. 1Pure. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by 1Pure and none should be inferred.